Biotalys H1 FY26 net loss widens to €9.14 million; IFRS operating loss deepens to €9.14 million

• Biotalys posted an IFRS net loss of EUR 9.14 million, widening from EUR 8.14 million a year earlier.
• Normalized net loss, excluding restructuring costs, narrowed to EUR 7.2 million, improving EUR 0.9 million year over year.
• Operating loss widened to EUR 9.14 million; restructuring costs totaled EUR 1.94 million, while R&D expenses slipped to EUR 6.15 million.
• Cash totaled EUR 11.9 million at June 30; net cash inflow was EUR 3.9 million, with runway seen through end-Q1 2027.
• Regulatory progress advanced for EVOCA in the U.S. and EU; CEO Carlo Boutton reiterated EVOCA NG launch targets of 2029 U.S., 2030 Europe.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biotalys NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608200100OMX_____CNEWS_EN_GNW9812860_en) on August 20, 2026, and is solely responsible for the information contained therein.